Meta-Analysis
Copyright ©The Author(s) 2023.
World J Clin Cases. Aug 6, 2023; 11(22): 5273-5287
Published online Aug 6, 2023. doi: 10.12998/wjcc.v11.i22.5273
Table 1 Main characteristics and baselines of the included studies
Ref.DesignCoutry/RegistryEnrollment periodDrug on DESControlOptimal stentingaNum of patientsMean age (yr)Male (%)Num of limbsNum of arteriesNum of lesionsMedian RCMean LRD (mm)Mean LL (mm)CTO (%)Follow up period (yr)b
Siablis et al[42], 2009PCSGreeceNASPTA+BMSIN vs N62 vs 4169 vs 7271 vs 9075 vs 47NA153 vs 775 vs 5NA55 vs 4525 vs 351
Karnabatidis et al[44], 2011ACSGreece2006-2009SPTA+BMSIY vs N47 vs 3471 vs 7174 vs 8251 vs 3675 vs 57102 vs 724 vs 5NA76 vs 7717 vs 351
Scheinert et al[45], 2012RCTACHILLES2008-2010SPTA±BMSIY vs N99 vs 10172 vs 7468 vs 75NANA113 vs 1154 vs 42.6 vs 2.627 vs 2781 vs 751
Rastan et al[26], 2012RCTGermany2006-2008SPTA+BMSIY vs Y82 vs 7973 vs 7268 vs 65NANA82 vs 794 vs 33.0 vs 3.030 vs 3123 vs 223
Bosiers et al[43], 2012RCTDESTINY2008-2009EPTA+BMSIY vs Y74 vs 6675 vs 7661 vs 5878 vs 7678 vs 7678 vs 764.5 vs 53.0 vs 2.916 vs 1915 vs 171
Spreen et al[24], 2017RCTPADI2007-2013PPTA±BMSIY vs N73 vs 6474 vs 7367 vs 7374 vs 66NA121 vs 915 vs 52.9 vs 2.921 vs 23NA3
Konijn et al[25], 2020RCTPADI2007-2013PPTA±BMSIY vs N73 vs 6474 vs 7367 vs 7374 vs 66NA121 vs 915 vs 52.9 vs 2.921 vs 23NA10
Zuzek et al[27], 2022RCSUSA2016-2017NAPTA+BMSINA1056 vs 76172 vs 7259 vs 64NANANA5 vs 5NANANA0.5